Success Metrics

Clinical Success Rate

92.6%

Based on 25 completed trials

Completion Rate

93%(25/27)

Active Trials

4(12%)

Results Posted

24%(6 trials)

Terminated

2(6%)

Phase Distribution

Ph not_applicable

Ph phase_2

12%

Ph phase_3

50%

Ph phase_4

18%

Ph phase_1

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution31 total trials

Phase 1Safety & dosage

2(6.5%)

Phase 2Efficacy & side effects

4(12.9%)

Phase 3Large-scale testing

17(54.8%)

Phase 4Post-market surveillance

6(19.4%)

N/ANon-phased studies

2(6.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

92.6%

25 of 27 finished

Non-Completion Rate

7.4%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(5)

Completed(25)

Terminated(2)

Other(2)

Detailed Status

Completed25

Recruiting3

Terminated2

unknown2

Active, not recruiting1

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

92.6%

Most Advanced

Phase 4

Trials by Phase

Phase 12 (6.5%)

Phase 24 (12.9%)

Phase 317 (54.8%)

Phase 46 (19.4%)

N/A2 (6.5%)

Trials by Status

recruiting39%

active_not_recruiting13%

completed2574%

not_yet_recruiting13%

terminated26%

unknown26%

Recent Activity

4 active trials

Showing 5 of 34

recruitingphase_2

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

NCT06676319

active_not_recruitingphase_3

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

NCT06473779

recruitingphase_3

Anti-Inflammatory Reliever South Africa

NCT06429475

completedphase_1

Cardiovascular Consequences of Inhaled Short-acting Beta-agonist Use

NCT06027606

not_yet_recruitingnot_applicable

Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEction

NCT06597682

View all 34 trials

Clinical Trials (34)

Showing 20 of 34 trialsScroll for more

NCT06676319Phase 2

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

Recruiting

NCT06473779Phase 3

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

Active Not Recruiting

NCT06429475Phase 3

Anti-Inflammatory Reliever South Africa

Recruiting

NCT06027606Phase 1

Cardiovascular Consequences of Inhaled Short-acting Beta-agonist Use

Completed

NCT06597682Not Applicable

Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEction

Not Yet Recruiting

NCT00576069

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

Recruiting

NCT04892732

Replication of the D58 Asthma Trial in Healthcare Claims Data

Completed

NCT03083067Not Applicable

Salvational Intervention for Reducing AECOPD Under Severe Air Pollution

Completed

NCT04663386

Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway

Terminated

NCT01070888Phase 4

Trial on the Effect of Budesonide/Formoterol and Inhaled Budesonide Alone on Exercise-Induced Asthma

Terminated

NCT01253473Phase 4

Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD)

Completed

NCT03478683Phase 4

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed

NCT03478696Phase 4

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed

NCT04171180Phase 4

The Efficacy of Budesonide/Formoterol in Cough Variant Asthma

Unknown

NCT02345161Phase 3

A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed

NCT03073057Phase 1

Pharmacokinetic Study to Compare Absorption of Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler

Completed

NCT01602523Phase 3

Effect of Symbicort on Sleep Quality in Patients With Emphysema

Unknown

NCT01560689Phase 2

Inhaled BUDESONIDE/FORMOTEROL in Bronchiolitis Obliterans Following Stem Cell Transplantation

Completed

NCT00989833Phase 2

Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients